Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRY103
- Development stage
- Preclinical
- Lead developer
- Bryleos
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRY103 is an investigational oral small molecule hormone being developed by Bryleos as a metabolic modulator. Utilizing Bryleos's proprietary LathMize platform, which is designed to enhance the stability and bioavailability of endogenous molecules, BRY103 acts as a metabolic rate regulator to modulate mitochondrial function. The candidate is currently in IND-enabling studies for the treatment of metabolic disorders, following a 505(b)(2) regulatory pathway.
Beyond the preview
Go deeper on BRY103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRY103.